Study summary
A gene-targeting drug cut convulsive seizures in children with Dravet syndrome
58.82%or greater median drop in convulsive seizures at the highest dose (open-label)
What was tested
Zorevunersen, an antisense drug given into the spinal fluid to raise levels of the NaV1.1 sodium channel that is missing in Dravet syndrome. Open-label, no comparison group.
What they found
- At the highest dose, median convulsive seizure reductions ranged from 58.82% to 90.91% over 20 months.
- Behavior and quality of life improved up to 36 months.
- Most side effects were mild; 2 children died of sudden unexpected death in epilepsy.
What it means
The first treatment aimed at the cause of Dravet syndrome; a phase 3 trial is under way.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.